secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001558370-22-008448
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q1 net loss widens to $0.70 per share; Phase 3 XLRP trial actively dosing
--------------------------------------------------------------------------------

- Net loss of $31.0M ($0.70 per share) vs $23.6M ($0.54) in Q1 2021; R&D spend rose to $23.1M.
- Cash and equivalents of $114M plus $13.1M Janssen receivable; runway into Q4 2023.
- Phase 3 Lumeos trial of botaretigene sparoparvovec for XLRP actively dosing patients; BLA submission targeted in 2024.
- Phase 1 AQUAx trial for radiation-induced xerostomia completed all cohorts; Phase 2 planned by year-end 2022.
- IND for AAV-GAD in Parkinson's filed May 2022; riboswitch platform advancing to first-in-human studies by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022008448/0001558370-22-008448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022008448/mgtx-20220512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer